LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

Search

Roivant Sciences Ltd

Closed

SectorHealthcare

10.65 -1.02

Overview

Share price change

24h

Current

Min

10.6

Max

10.86

Key metrics

By Trading Economics

Income

212M

25M

Sales

4.5M

9M

EPS

-0.199

Profit margin

280.018

Employees

908

EBITDA

-52M

-274M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+63.79% upside

Market Stats

By TradingEconomics

Market Cap

7.8B

Previous open

11.67

Previous close

10.65

News Sentiment

By Acuity

50%

50%

187 / 382 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Roivant Sciences Ltd Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 maj 2025, 23:40 UTC

Hot Stocks

Stocks to Watch: UnitedHealth Group, Foot Locker, CoreWeave

14 maj 2025, 23:33 UTC

Major Market Movers

UnitedHealth Group Shares Fall After WSJ Reports of Investigation for Possible Medicare Fraud

14 maj 2025, 23:25 UTC

Major Market Movers

Biohaven Shares Down as FDA Extends PDUFA Data for Troriluzole

14 maj 2025, 23:25 UTC

Earnings

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth -- Update

14 maj 2025, 22:58 UTC

Earnings

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth

14 maj 2025, 21:35 UTC

Earnings

Cisco Systems Names Patterson as CFO, Patel as President

14 maj 2025, 23:59 UTC

Market Talk

Implications of Xero's Cost Outlook Aren't Clear -- Market Talk

14 maj 2025, 23:49 UTC

Market Talk

Xero's Cost Outlook Likely to Prompt Downgrades -- Market Talk

14 maj 2025, 23:48 UTC

Market Talk

Global Equities Roundup: Market Talk

14 maj 2025, 23:48 UTC

Market Talk

Nikkei May Decline on Profit-Taking After Recent Gains -- Market Talk

14 maj 2025, 23:47 UTC

Market Talk

Gold Gains on Possible Technical Recovery -- Market Talk

14 maj 2025, 23:34 UTC

Acquisitions, Mergers, Takeovers

Agnico-Eagle Mines to Subscribe for 30M Voting Common Shares of Foran Mining in Non-Brokered Private Placement at C$3 a Share

14 maj 2025, 23:10 UTC

Earnings

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth -- Update

14 maj 2025, 23:07 UTC

Earnings

CoreWeave Posts Strong Revenue and Wins Google as a Customer. Stock Still Dives on Outlook. -- Barrons.com

14 maj 2025, 23:00 UTC

Top News

UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud -- WSJ

14 maj 2025, 22:43 UTC

Earnings

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth

14 maj 2025, 22:34 UTC

Earnings

Xero Expects 1H Operating Expense Ratio to Be Higher Than 2H>XRO.AU

14 maj 2025, 22:33 UTC

Earnings

Xero Expects FY26 Operating Expense Ratio of 71.5%>XRO.AU

14 maj 2025, 22:30 UTC

Earnings

Xero Did Not Declare a Dividend>XRO.AU

14 maj 2025, 22:30 UTC

Earnings

Xero FY Operating Expenses 71.8% of Operating Revenue Vs. 73.3%>XRO.AU

14 maj 2025, 22:30 UTC

Earnings

Xero FY Free Cashflow Margin 24.1% Vs. 20.0%>XRO.AU

14 maj 2025, 22:30 UTC

Earnings

Xero FY Free Cashflow NZD506.7M Vs. NZD342.1M>XRO.AU

14 maj 2025, 22:28 UTC

Earnings

Xero FY Ebitda NZD638.5M Vs. NZD497.4M>XRO.AU

14 maj 2025, 22:28 UTC

Earnings

Xero FY Adjusted Ebitda NZD640.6M Vs. NZD526.5M>XRO.AU

14 maj 2025, 22:27 UTC

Earnings

Xero FY Rev NZD2.10B Vs. NZD1.71B >XRO.AU

14 maj 2025, 22:27 UTC

Earnings

Xero FY Net NZD227.8M Vs. Net NZD174.6M >XRO.AU

14 maj 2025, 22:23 UTC

Top News

Boeing, GE Aerospace Get Qatar Airways Order After Saudi AI Tech Deals -- 2nd Update

14 maj 2025, 22:15 UTC

Earnings

Correction to Cisco Earnings Article -- WSJ

14 maj 2025, 21:48 UTC

Earnings

CoreWeave Posts Strong Revenue but Stock Dives on Updated Outlook -- Barrons.com

14 maj 2025, 21:37 UTC

Earnings

Cisco Reports Solid Earnings. The Stock Is Rising. -- Barrons.com

Peer Comparison

Price change

Roivant Sciences Ltd Forecast

Price Target

By TipRanks

63.79% upside

12 Months Forecast

Average 18 USD  63.79%

High 18 USD

Low 18 USD

Based on 5 Wall Street analysts offering 12 month price targets forRoivant Sciences Ltd - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

11 / 11.18Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

187 / 382 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.